Cancer drug startup Cargo raises $200M to solve CAR-T relapse

A biotechnology startup has raised $200 million from a group of blue-chip investors to develop a new kind of cancer cell therapy for people with lymphoma whose cancer has relapsed or grown resistant to existing cellular treatments.